1. Home
  2. LPTX vs AOUT Comparison

LPTX vs AOUT Comparison

Compare LPTX & AOUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LPTX
  • AOUT
  • Stock Information
  • Founded
  • LPTX 2011
  • AOUT 2020
  • Country
  • LPTX United States
  • AOUT United States
  • Employees
  • LPTX N/A
  • AOUT N/A
  • Industry
  • LPTX Biotechnology: Biological Products (No Diagnostic Substances)
  • AOUT Ordnance And Accessories
  • Sector
  • LPTX Health Care
  • AOUT Industrials
  • Exchange
  • LPTX Nasdaq
  • AOUT Nasdaq
  • Market Cap
  • LPTX 119.6M
  • AOUT 142.1M
  • IPO Year
  • LPTX N/A
  • AOUT N/A
  • Fundamental
  • Price
  • LPTX $0.36
  • AOUT $11.63
  • Analyst Decision
  • LPTX Buy
  • AOUT Strong Buy
  • Analyst Count
  • LPTX 2
  • AOUT 2
  • Target Price
  • LPTX $8.00
  • AOUT $15.50
  • AVG Volume (30 Days)
  • LPTX 381.5K
  • AOUT 58.6K
  • Earning Date
  • LPTX 05-20-2025
  • AOUT 06-26-2025
  • Dividend Yield
  • LPTX N/A
  • AOUT N/A
  • EPS Growth
  • LPTX N/A
  • AOUT N/A
  • EPS
  • LPTX N/A
  • AOUT N/A
  • Revenue
  • LPTX N/A
  • AOUT $206,678,000.00
  • Revenue This Year
  • LPTX N/A
  • AOUT $5.93
  • Revenue Next Year
  • LPTX N/A
  • AOUT $6.60
  • P/E Ratio
  • LPTX N/A
  • AOUT N/A
  • Revenue Growth
  • LPTX N/A
  • AOUT 4.91
  • 52 Week Low
  • LPTX $0.22
  • AOUT $7.79
  • 52 Week High
  • LPTX $4.79
  • AOUT $17.91
  • Technical
  • Relative Strength Index (RSI)
  • LPTX 45.04
  • AOUT 50.83
  • Support Level
  • LPTX $0.32
  • AOUT $11.22
  • Resistance Level
  • LPTX $0.38
  • AOUT $12.00
  • Average True Range (ATR)
  • LPTX 0.03
  • AOUT 0.61
  • MACD
  • LPTX 0.00
  • AOUT 0.17
  • Stochastic Oscillator
  • LPTX 37.36
  • AOUT 72.88

About LPTX Leap Therapeutics Inc.

Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .

About AOUT American Outdoor Brands Inc.

American Outdoor Brands Inc is engaged in the business of providing outdoor products and accessories for hunting, fishing, camping, shooting, and personal security and defense products. The company designs and produces products and accessories, including shooting supplies, rest, vaults, and other related accessories; premium sportsman knives and tools for fishing and hunting; land management tools for hunting preparedness; harvesting products for post-hunt or post-fishing activities; electro-optical devices, including hunting optics, firearm aiming devices, flashlights, and laser grips; reloading, gunsmithing, and firearm cleaning supplies; and survival, camping, and emergency preparedness products.

Share on Social Networks: